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ABSTRACT
Introduction: Chronic obstructive pulmonary disease
(COPD) is a heterogeneous disease with pulmonary
and extra-pulmonary manifestations. Although COPD is
a complex disease, diagnosis and staging are still
based on simple spirometry measurements. Different
COPD phenotypes exist based on clinical,
physiological, immunological and radiological
observations. Cigarette smoking is the most important
risk factor for COPD, but only 15–20% of smokers
develop the disease, suggesting a genetic
predisposition. Unfortunately, little is known about the
pathogenesis of COPD, and even less on the very first
steps that are associated with an aberrant response to
smoke exposure. This study aims to investigate the
underlying local and systemic inflammation of different
clinical COPD phenotypes, and acute effects of
cigarette smoke exposure in individuals susceptible
and non-susceptible for the development of COPD.
Furthermore, we will investigate mechanisms
associated with corticosteroid insensitivity. Our study
will provide valuable information regarding the
pathogenetic mechanisms underlying the natural
course of COPD.
Methods and analysis: This cross-sectional study
will include young and old individuals susceptible or
non-susceptible to develop COPD. At a young age
(18–40 years) 60 ‘party smokers’ will be included who
are called susceptible or non-susceptible based on
COPD prevalence in smoking family members. In
addition, 30 healthy smokers (age 40–75 years) and
110 COPD patients will be included. Measurements will
include questionnaires, pulmonary function, low-dose
CT scanning of the lung, body composition, 6 min
walking distance and biomarkers in peripheral blood,
sputum, urine, exhaled breath condensate, epithelial
lining fluid, bronchial brushes and biopsies. Non-
biased approaches such as proteomics will be
performed in blood and epithelial lining fluid.
Ethics and dissemination: This multicentre study
was approved by the medical ethical committees of
UMC Groningen and Utrecht, the Netherlands.
The study findings will be presented at
conferences and will be reported in peer-reviewed
journals.
Trial registration: ClinicalTrials.gov, NCT00807469
(study 1) and NCT00850863 (study 2).
ARTICLE SUMMARY
Article focus
▪ This article describes the study protocol of a cross-
sectional study investigating the underlying local
and systemic inflammation of different clinical
Chronic obstructive pulmonary disease (COPD)
phenotypes, and acute effects of cigarette smoke
exposure in individuals susceptible and non-
susceptible for the development of COPD.
Key messages
▪ Young (18–40) and older (40–75) individuals
who are susceptible and non-susceptible to
develop COPD are included.
▪ All groups are extensively phenotyped by clinical,
physiological, immunological and radiographical
characterisation. Furthermore, effects of acute
smoking are studied.
Strengths and limitations of the study
▪ Extensive characterisation of a well-defined study
population, providing valuable information regard-
ing the pathogenic mechanisms underlying the
natural cause of COPD.
▪ Recruitment of a population with high and low
familiar risk to develop COPD.
Lo Tam Loi AT, Hoonhorst SJM, Franciosi L, et al. BMJ Open 2013;3:e002178. doi:10.1136/bmjopen-2012-002178 1
Open Access Protocol
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality worldwide.1 The
disease is characterised by persistent and progressive
expiratory airﬂow obstruction (postbronchodilator
FEV1/FVC<0.70) and its severity is based on FEV1%pre-
dicted.1 Cigarette smoking is the most important risk
factor for COPD in the western world, but only 15–20%
of young smokers will eventually develop the disease, sug-
gesting a genetic predisposition. So far, the genetic back-
ground of these susceptible smokers has not been
elucidated.2 Unravelling the underlying pathogenetic
mechanisms of COPD is difﬁcult because it takes
20–30 years of smoking before susceptible smokers
develop established COPD. Also, there is the problem
that COPD has many clinical expressions, and we recently
have started to learn how to phenotype this heteroge-
neous disease. Finally, there are many other risk factors
that may modulate the complex interaction between the
genetic background and smoking, like in utero events,
microbial infections, dietary factors, physical inactivity
and pharmacological treatment.
It is well accepted that the spirometry measurements
(FEV1 and FVC) are largely insufﬁcient to diagnose and
classify COPD.1 With the increased recognition of
various clinical expressions of COPD, consensus is
growing that COPD represents a spectrum of overlap-
ping diseases with important extra-pulmonary conse-
quences. Phenotypes of COPD may be classiﬁed
according to four domains: clinical, physiological,
immunological and radiographical.3
▸ Clinical distinctions are generally based on dyspnoea
scores, frequency of exacerbations, body mass, muscle
wasting, corticosteroid responsiveness, depression/
anxiety, comorbidity and healthy status.4
▸ Physiological distinctions may be based on the
degree of airﬂow limitation, decline in lung func-
tion, bronchodilator responsiveness, airway hyper-
responsiveness, CO diffusion capacity, hyperinﬂa-
tion, body-plethysmography, bio-impedance and
exercise tolerance.
▸ Immunological features comprise the type and sever-
ity of local and systemic immunological processes
in the lung and systemic compartment. In blood
leucocytes, cytokines and mediators may affect the
functionality of extra-pulmonary tissues and organs,
leading to COPD-associated comorbid conditions.
▸ Radiographic distinctions may be based on the pres-
ence of various forms and severity of emphysema,
thickened large airways and small airways abnormality
on high-resolution CT scans.
Although systemic inﬂammation and multiorgan path-
ology have been put forward as important features of
COPD, surprisingly little is known about the underlying
pathogenesis. Most COPD studies in this ﬁeld included
small numbers of individuals, focused on more severe
stages of COPD, characterised subjects clinically on the
basis of a few arbitrary pulmonary measurements, did
not take into account the genetic background and paid
limited attention to different aspects of systemic inﬂam-
mation. In addition, most studies assumed that assess-
ment of cytokines by multiplex assays (eg, Luminex) is
sufﬁcient to accurately describe the systemic inﬂamma-
tory response. Unfortunately, many caveats are present
that preclude a complete insight in this response, for
example:
▸ Not all cytokines implicated in COPD are known;
▸ Little effort is taken to measure anti-inﬂammatory
cytokines (the balance between proinﬂammatory and
anti-inﬂammatory signals will probably determine the
extent and type of inﬂammation);
▸ Different proinﬂammatory cytokines can act as heter-
ologous antagonists (inhibit the effects of other
cytokines);
▸ The kinetics of cytokines are very dynamic and no
consensus is present regarding an optimal single time
point for blood collection.
In the present study we set out to characterise systemic
inﬂammation by an alternative approach. Innate immune
cells will be used as integrators of proinﬂammatory and
anti-inﬂammatory signals. We hypothesise that subtle
changes in the phenotype of granulocytes and monocytes
are caused by an ‘inﬂammatory imprinting’ of these cells.
Cigarette smoking is the main risk factor for develop-
ing COPD. Repetitive acute effects of cigarette smoke
exposure may accumulate and after many years lead to
irreversible lung damage. To understand the changes in
the lung due to chronic smoking we believe that it is
important to ﬁrst investigate the exact immunological
responses to an acute smoke exposure event, particularly
in ‘naive’ lungs that are not yet affected by chronic
smoke exposure. The acute (<24 h) effects of smoking
in humans, animals and cell cultures have been exten-
sively reviewed some years ago by van der Vaart et al.5 If
we integrate all the available data on acute smoking we
are able to construct a hypothetical time frame for acute
effects of smoking (ﬁgure 1). One of the very ﬁrst
insults on the bronchial system is by oxidants present in
cigarette smoke. After local depletion of antioxidants,
the ﬁrst oxidative stress products can be measured
within 1 h. These products will disappear within 6 h.
There is a surprisingly fast inﬂux of inﬂammatory cells;
even faster than the synthesis of some pro-inﬂammatory
cytokines (tumour necrosis factor (TNF) α, interleukin
(IL)-1β, IL-8). The exact time period at which the pro-
teinase/antiproteinase balance is affected is unknown;
however, protein degradation is measurable within 6 h
after smoking. Unfortunately, until now, only a few
studies have investigated the acute effects of cigarette
smoking in humans.5 These studies included only small
numbers of individuals, characterised subjects mainly on
basis of pulmonary measurements, paid no attention to
the genetic background and paid limited attention to
different aspects of pulmonary inﬂammation.
Corticosteroids provide little therapeutic beneﬁt in a
relatively large group of COPD patients, despite their
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broad anti-inﬂammatory effects. Our goal is to identify
common markers in peripheral blood monocytes, skin
and lung epithelial cells that might contribute to cortico-
steroid insensitivity. Recently, the GLUCOLD study
demonstrated beneﬁcial effects on airway wall inﬂamma-
tion and decline in lung function yet with large interindi-
vidual differences.6 In vitro studies have shown that the
ability of dexamethasone to suppress cytokine release
(eg, IL-8) from alveolar macrophages are impaired in
COPD patients as compared with healthy smokers.7
Furthermore, alveolar macrophages from healthy
smokers are more resistant to corticosteroids than macro-
phages from non-smokers.8 This relative steroid insensi-
tivity may, in part, be explained by a suppressive effect of
cigarette smoke-induced oxidative stress. This suppres-
sion may particularly play a role in the airway epithelium,
where cells are in ﬁrst contact with cigarette smoke and
form an important source of mediators involved in the
induction of neutrophilic airway inﬂammation (eg, the
chemoattractant IL-8). It may well be that corticosteroid
insensitivity is gradually acquired by smoking in COPD,
and one might hypothesise that smokers who develop
COPD are more prone to have signs of corticosteroid
insensitivity.
General hypotheses
There is a clear need to understand all the factors that
contribute to the development of COPD and its differ-
ent phenotypes better. This study focuses on the patho-
genesis and clinical expression of smoking-induced
COPD, studied both in the pulmonary and the systemic
compartments. The following general hypothesis is put
forward by our consortium (ﬁgure 2):
COPD is a multi-organ disease situated in both the lung
and extra-pulmonary organs and tissues. Dysfunction of
the latter tissues is exempliﬁed by muscle atrophy,
impaired muscle oxidative capacity, osteoporosis, athero-
sclerosis and heart failure. A low-grade systemic inﬂam-
mation plays a pivotal role in the induction and
perpetuation of this multi-organ disease. Smoking and
persistent production of inﬂammatory mediators from
the lung are inducers of systemic inﬂammation. Other
risk factors such as diet deﬁciencies, sedentary life style
and frequent infections contribute independently to
further ampliﬁcation of systemic inﬂammation. In more
advanced COPD the extra-pulmonary pathology starts to
contribute to disease severity and a vicious circle of per-
sistent difﬁculty to treat inﬂammation. Consequently,
local and systemic inﬂammation should be reduced in all
stages of disease by reversing negative lifestyle factors and
applying successful anti-inﬂammatory treatment modal-
ities. In more advanced stages multimodal interventions
additionally should improve impaired tissue functions.
Figure 2 General hypothesis
about the role of systemic
inflammation.
Figure 1 Acute smoking effects in the lung.
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An important contributing problem is the relative cor-
ticosteroid insensitivity of both lung and peripheral tissue
responses in COPD.
Aims of the study
▸ To assess systemic and local inﬂammation at baseline
in:
– Young healthy individuals with low number of pack
years smoking who have a high and low familial risk
to develop COPD;
– Older individuals with higher number of pack years
who either have normal lung function or COPD.
We hypothesise that young susceptible individuals
and COPD patients demonstrate a higher degree
and different type of local and systemic inﬂamma-
tion at baseline.
▸ To study systemic and local inﬂammation after acute
smoke exposure in the above groups. We hypothesise
that young susceptible individuals and COPD patients
demonstrate a higher and aberrant local and systemic
inﬂammatory response to cigarette smoke.
▸ To compare in bronchial epithelial cells and periph-
eral blood mononuclear cells (PBMCs) corticosteroid
responsiveness in vitro between susceptible and non-
susceptible individuals. To study in these cells the
effects of cigarette smoking and to elucidate under-
lying mechanisms of corticosteroid unresponsiveness.
▸ To determine whether the type and severity of the sys-
temic inﬂammatory response contributes to the clin-
ical outcome of COPD. We hypothesise that the type
and severity of systemic inﬂammation have profound
effects on the clinical picture of COPD.
▸ To investigate the relationship between downstream
genetic effects (transcriptome and proteome) and
speciﬁc COPD phenotypes in peripheral blood and




In total, 200 old and young individuals who are suscep-
tible or not susceptible to develop COPD will be
recruited (table 1). At old age (>40 years), 30 healthy
smokers (>20 pack years) and 110 COPD patients (>10
pack years) will be enrolled in the study. At a young age,
60 ‘party smokers’ with a normal lung function will be
included with a high or low prevalence of COPD in
smoking family members (see table 1). Party smoking was
deﬁned by irregularly smoking and/or able to quit
smoking for at least 2 days. Exclusion criteria are:
α-1-antitrypsin deﬁciency, acute pulmonary infections
(like tuberculosis, pneumonia, ﬂu and tracheo-
bronchitis), prior history of signiﬁcant inﬂammatory lung
disease other than COPD (sarcoidosis, pulmonary ﬁbro-
sis, silicosis, etc), active infections (such as hepatitis A–C,
cystitis, gastroenteritis, etc), treatment with antibiotics or
corticosteroids within 8 weeks, taking part in another
study and recent diagnosis of cancer. Medication such
as non-steroidal anti-inﬂammatory drugs and immuno-
suppressive agents which could affect the results of the
study will be excluded, as well as substance abuse.
Comorbidities that might lead to study-related (serious)
adverse events will be excluded on the basis of an arbi-
trary selection of conditions listed in the ACE-27
comorbidity scale.9
Study design
This study is a bi-centre cross-sectional study that
takes place at University Medical Centers Utrecht
(UMC Utrecht) and Groningen (UMC Groningen).
Participating subjects will undergo extensive clinical
characterisation (table 2). Local and systemic inﬂamma-
tion will be investigated in several ways. Special attention
will be paid to acute smoking and corticosteroid insensi-
tivity in selected subgroups.
Table 1 Study population
Disease No Age (years) Smoking status Pack years FEV1/VC (%) FEV1 (% predicted)
Non-susceptible
Healthy (A) 30 18–40 Party smoking 0–10 >70 >85
Healthy (B) 30 40–75 Ex or current >20 >70 >85
Susceptible
Healthy (C) 30 18–40 Party smoking 0–10 >70 >85
COPD
Stage I (D1) 30 40–75 Ex or current >10 ≤70 >80
Stage II (D2) 30 40–75 >10 ≤70 50–80
Stage III (D3) 30 40–75 >10 ≤70 30–50
Stage IV (D4)* 20 40–75 >10 ≤70 <30
<53 <30%
Susceptibility in young individuals is based on family history. Not susceptible means that none of the smoking family members who are
at least 40 years of age have COPD. Susceptible means that the prevalence of COPD in smoking family members older than 40 years is
high: 2 of 2, 2 of 3 or 3 of 3, 3 of 4 or 4 of 4. Party smoking was defined by irregularly smoking and/or able to quit smoking for at least
2 days. α-1-antitrypsin deficiency is excluded.
*Patients with a FEV1 30–50% predicted in combination with chronic respiratory failure also have stage IV.
COPD, chronic obstructive pulmonary disease.
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Clinical outcomes
Demographic variables include: age, sex, smoking habits,
education, profession, other exposures, height and
weight. Risk factors of the metabolic syndrome will be
determined including blood pressure, waist hip circum-
ference, lipid proﬁle and fasting glucose (table 2).
Questionnaires will be the Clinical COPD Questionnaire
(CCQ), the St George’s Respiratory Questionnaire
(SGRQ), the Dutch Fagerstrom test for nicotine depend-
ence and the Short QUestionnaire to ASsess
Health-enhancing physical activity (SQUASH).10–12
Exacerbation frequency will be recorded in COPD
patients. The BODE-index will be calculated on the basis
of FEV1, 6 min walking distance (6MWD), body mass
index (BMI) and MRC-dyspnoea score.4 In urine (micro)
protein concentration will be assessed. Corticosteroid
sensitivity will be measured by cutaneous vasoconstrictor
response to topical budesonide using the skin blanching
test.13 Budesonide dissolved in 95% ethanol will be
applied to the skin using eight different concentrations
(0–1000 μg/ml). Blanching will be scored with a 7-point
scale: 0–3 (increasing with steps of 0.5; 0=no blanching
and 3=intense blanching). Cumulative oxidative stress
will be measured in the skin using the non-invasive
advanced glycation endproducts (AGE) reader
(DiagnOptics, Groningen, The Netherlands).14
Physiological outcomes
Spirometry will be performed according to international
guidelines (ERS 2005).15 We will assess FEV1, FEV1/FVC,
IVC, FEF50, FEF75, reversibility to salbutamol, TLC,
FRC (body box) and CO diffusion. Methacholine chal-
lenge tests are performed according to international
guidelines (ERS 2005), using serial doubling concentra-
tions of methacholine-bromide (0.03–38.4 mg/ml) with
the 2 min tidal breathing method at 5 min intervals. The
6MWD will be determined according to the American
Thoracic Society published guidelines of 2002.16
Individuals should walk at their own pace, can stop if
necessary and are allowed to use oxygen. Body compos-
ition will be estimated using single frequency (50 kHz)
bioelectrical impedance (Biostat 500), and fat-free mass







Peripheral blood (routine measurements) All
Presence of metabolic syndrome All
ECG B, D1-4
BODE index B, D1-4
Fagerstrom Smoking Questionnaire All
St George’s Respiratory Questionnaire (SGRQ) D1-4
Clinical COPD (chronic obstructive pulmonary disease) Questionnaire (CCQ) D1-4
SQUASH All
Urine (microproteins) All
AGE (Advanced Glycation Endproducts)-reader All





Methacholine challenge test A, B, C, D1-3
Bioelectrical impedance All
Six minute walking distance B, D1-4
Immunological
Sputum induction (only baseline) A, B, C, D2
Peripheral blood (systemic inflammation) All
Peripheral blood 4× (acute smoking) A, B, C, D2
Exhaled breath condensate 3× (acute smoking) A, B, C, D2
Exhaled CO 5× (acute smoking) A, B, C, D2
Bronchial biopsy 2× (acute smoking) A, B, C, D2
Epithelial lining fluid 2× (acute smoking) A, B, C, D2
Epithelial brushes 2× (acute smoking) A, B, C, D2
Radiographical
Low dose HRCT-scan lung All
HRCT, high resolution computed tomography.
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Immunological outcomes
Lung inflammation
▸ Sputum will be induced and processed according to a
validated and standardised technique,18 with some
modiﬁcations. Differential cell counts of eosinophils,
neutrophils, lymphocytes, macrophages and epithelial
and squamous cells will be performed on May
Grünwald Giemsa (MGG)-stained cytospins by a
qualiﬁed cytopathologist.
▸ Exhaled breath condensate will be collected using
the EcoScreen ( Jaeger, Hoechberg, Germany).
Hydrogen peroxide, pH, 8-isoprostane, nitrite,
nitrate, 4-hydroxy-2-nonenal and malondialdehyde
will be measured.
▸ Bronchoscopy will be performed using established
guidelines,19–21 and six bronchial biopsies will be
taken from subsegmental carinae in the right or left
lower lobe. Epithelial morphology, epithelial prolifer-
ation and basement membrane thickness will be mea-
sured.22 Submucosal density of inﬂammatory cells
(AA1, EG2, CD68, CD3, CD4, CD4CD25, CD8, mast
cells and neutrophils) will be quantitated in a semiau-
tomated way.22 Expression of E-cadherin, vascular
endothelial growth factor, intercellular adhesion mol-
ecule, vascular cell adhesion molecule, E-selectin,
P-selectin, AGEs and receptor for advanced glycation
end-products will be measured.
▸ Epithelial lining ﬂuid will be sampled by advancing
three microsample probes (BC-401C, Olympus, Tokyo,
Japan) in the lumen of the left main bronchus.23 24
Cytokines will be measured by Luminex (Linco,
Nuclilab BV, Ede, The Netherlands). Ninety per cent of
the epithelial lining ﬂuid (ELF) will be used for prote-
omic analysis. Brieﬂy, each trypsin-digested sample will
be labelled (iTRAQ Reagent 8-plex, ABSciex, Foster
City, California, USA) according to the manufacturer’s
protocol. The individually labelled digests will be com-
bined into a single-sample mixture and subjected to
strong cation-exchange chromatography (AKTA
Puriﬁer, GE Healthcare Biosciences AB, Uppsala,
Sweden). The resulting peptide-containing fractions will
be separated by reversed-phase chromatography
(Ultimate 3000 nanoﬂow liquid chromatography system,
Dionex, Amsterdam, The Netherlands). Fractions of
12 s will be spotted on matrix-assisted laser-desorption
ionisation (MALDI) targets (Probot, Dionex,
Amsterdam, The Netherlands) and mass spectrometric
analysis will be carried out on a 4800 Proteomics
Analyzer MALDI TOF/TOF instrument (Applied
Biosystems, Foster City, California, USA) controlled by
the 4000 Series Explorer V.3.5 software. Proteins will be
identiﬁed using Protein Pilot software V.2.0 (Applied
Biosystems).
▸ Bronchial epithelial cells will be harvested from the
right or left main bronchus by brushing as described
elsewhere.25 Brushed epithelial cells will be cultured
to enable corticosteroid sensitivity experiments. In
these experiments, cultured bronchial epithelial cells
will be incubated in vitro with steroids and the effects
on chemokine production (IL-8, growth regulated
oncogene-alpha (GRO-α) and regulated and normal
T cell expressed and secreted (RANTES)) and MMP/
TIMP expression (mRNA) will be established. In add-
ition, in PBMC the following parameters will be
studied: (1) plasma levels of chemokines/inﬂamma-
tory cytokines, (2) in vitro effects of steroids on
TNF-α, IL-1β, IL-10, TGF-β, signalling pathways
(western/electrophoretic mobility shift assay), toll-like
receptors and CD14 expression as well as genes with
a glucocorticoid response element (GRE) in their
promoter, for example, β2-adrenergic receptor, map-
kinase phosphatase-1 (MAPKP-1, FoxP3 (ELISA/
RTPCR).
Systemic inflammation
Systemic inﬂammation will be measured in peripheral
blood using several methods to study systemic activation
of innate immune cells at four different levels:
▸ Expression of established and new markers on innate
immune cells associated with preactivation.26 27 The
established markers include proteins that are upregu-
lated on the cell surface upon activation of neutro-
phils in vitro, and can be measured by ﬂow cytometry:
CD11b (Mac-1), CD18 (integrin β2 chain), CD66b
(CAECAM-8) and CD63 (LAMP-3). New markers
directed against active integrins and Fc-receptors have
been shown to be useful in detecting more subtle acti-
vation such as induced by cytokines: active Mac-1
(CD11b/clone CBRM1/5 28), active β1-integrin chain
(CD29/ clone N2929) and active FcγRII (CD32/clones
A1730). These latter markers will be used to detect
subtle priming signals affecting the function of leuco-
cytes in peripheral blood.
▸ Determination of the sensitivity of innate immune cells
for stimuli. One of the ﬁrst changes which can be
observed in response to inﬂammatory stimuli in vivo is a
change in sensitivity for innate immune stimuli such as
fMet-Leu-Phe (fMLF). Little activation is associated with
an enhanced responsiveness, whereas pronounced sys-
temic activation is associated with decreased responsive-
ness for fMLF.31 Therefore, the responsiveness of
leucocytes for fMLF will be measured as a read-out for
systemic inﬂammatory signals in vivo.
▸ Genomic and proteomic analysis of innate immune
cells in vivo.32 Total mRNA and proteins are collected
from leucocytes and will be analysed by unsupervised
genomic and proteomics techniques. Proteomics will
be carried out by 2D-difference gel electrophoresis
(2D-DIGE).33
▸ Multiplex analysis of the presence of proinﬂammatory
and anti-inﬂammatory cytokines in plasma/serum.
Serum samples will be analysed for the presence of
multiple cytokines and chemokines by luminex
technology.34
Systemic inﬂammation will also be measured in periph-
eral blood using PBMCs:
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▸ Expression of intracellular and cell-surface markers of
adaptive immune cells (Th1, Th2, Th17, Treg, B and
natural killer cells) will be measured by ﬂow cytometry.
Lung and systemic inflammation after acute smoking
Young and old subjects who are susceptible or not sus-
ceptible to develop COPD will smoke three cigarettes in
1 h. Exhaled CO, blood samples and urine, exhaled
breath condensate, bronchial biopsies, epithelial lining
ﬂuid and epithelial brushes will be collected at baseline
and after smoking according to the scheme in table 3.
Exhaled CO will be measured at baseline to check if
individuals did not smoke recently, and after smoking to
check if individuals inhaled cigarette smoke sufﬁciently.
A ﬁrst bronchoscopy will be performed after 24 h.
Bronchial biopsies, epithelial brushes and microprobe
sampling of epithelial lining ﬂuid will be collected. Six
weeks after the acute smoking procedure a second bron-
choscopy will be performed as a baseline measurement,
obtaining the same specimen.
Samples collected at baseline and during the acute
smoking procedure including sputum supernatant, serum,
plasma, DNA and RNA of blood, urine, exhaled breath
condensate, epithelial lining ﬂuid, epithelial brushes and
bronchial biopsies will be stored for further analyses.
Radiological outcomes
All subjects will undergo a low-dose CT scan at full
inspiration and expiration. Exposure settings will be
30 mAs at 90 kVp for patients weighing less then 50 kg,
30 mAs at 120 kVp for patients weighing between 50 and
80 kg and 30 mAs at 140 kVp for those weighing more
than 80 kg without dose modulation. During expiration
the exposure settings will be 20 mAs at 90 kVp (body
mass <80 kg) or 20 mAs at 120 kVp (body mass >80 kg).
Emphysematous lung changes will be quantitated using
automated software on low-dose CT scanning images
developed in UMC Utrecht.
Sample size calculation
We concluded that the limited data in the literature do not
allow us to calculate a reliable sample size according to a
formal power-analysis. In general, 20–30 subjects per
group are needed in studies to detect a signiﬁcant proin-
ﬂammatory or anti-inﬂammatory effect in sputum, BAL or
bronchial biopsies. Looking to the available acute smoking
studies in the literature this seems sufﬁcient to detect an
effect at least in exhaled breath condensate.
Statistical analyses
Demographic variables such as age, sex, smoking habits,
education, work, other exposures, height and weight
will be expressed as means (SD) or medians (IQR) as
appropriate for continuous variables, and number (per-
centages) for dichotomous variables, according to
group. Exacerbation frequency will be described (with
percentage) per groups. Spirometry data (FEV1, FEV1/
FVC, IVC, FEF50, FEF75, reversibility to salbutamol,
TLCO TLC, FRC (body box), CO diffusion and metha-
choline challenge tests), and data indicative of systemic
inﬂammation will be described similarly.
Comparisons between groups with regard to all the afore-
mentioned variables will be tested using χ2 tests in case of
comparison of proportions, and parametric (like the
unpaired t test) or non-parametric tests (like the M-W-U
test/Wilcoxon rank sum) as appropriate according to the
distribution of the residuals. To test changes within groups
over time at various visits, additionally paired variants of
the before-mentioned tests will be used as appropriate (eg,
the paired-t test and the Wilcoxon signed rank test).
Linear or logistic regression will be used to further
analyse differences between groups in the aforemen-
tioned outcome variables taking confounding factors into
account. Techniques like linear mixed effects models will
be used to estimate changes in variables over time.
Ethics and dissemination
The two studies are registered at clinicaltrial.gov (identi-
ﬁer study 1: NCT00807469 and identiﬁer study 2: NCT
00850863). These two studies have been judged by the
medical ethical committee of UMC Groningen and add-
itionally study 2 has been minimally judged by the
medical ethical committee of UMC Utrecht. The study
ﬁndings will be presented at conferences and will be
reported in peer-reviewed journals.
DISCUSSION
There is a large backlog in the recognition of different
phenotypes of COPD and their underlying immuno-
pathological processes. This importantly hinders the
appropriate diagnosis, treatment and prognosis of this
Table 3 Acute smoke model
Baseline Smoking three cigarettes 5 min 2 h 24 h 6 weeks
Exhaled CO x x x x x
Blood x x
Exhaled breath condensate x x x
Urine x x x
Bronchial Biopsies x x
Epithelial brush x x
Microsampling probe (ELF) x x
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disabilitating disease. Currently, lung function (FEV1
and FEV1/FVC) is still the standard for the diagnosis
and classiﬁcation of COPD.1 However, there is general
consensus that FEV1 poorly correlates with important
patient-centred outcomes such as quality of life, symp-
toms and exercise capacity.35 Celli et al4 showed an asso-
ciation between FEV1 and mortality when FEV1 was
combined with MRC-dyspnoea score, 6MWD and BMI.
The so-called BODE index was put forward as a compos-
ite measure to characterise COPD in a more realistic
way. In the last decade different approaches have been
put forward to characterise COPD leading to at least 16
different phenotypes.36 Although clinically relevant in
terms of presentation, triggers and treatment response
these phenotypes do not necessarily give insight into the
underlying disease processes of COPD. In this perspec-
tive the term intermediate phenotype or endotype has
been put forward to describe a subtype of a disease
which is deﬁned by a distinct functional or pathophysio-
logical mechanism.37 Together with genetic and environ-
mental factors intermediate phenotypes may explain
the clinical presentation of a heterogeneous disease like
COPD. Accordingly, the present study will phenotype
the induction and progression of COPD and associate
this with underlying pathophysiological mechanisms in a
biased as well as non-biased way. As smoking is the
most important environmental risk factor for COPD we
will use an acute smoking model to evaluate differences
in smoking-induced acute mechanisms differentially
expressed between individuals with a high and low risk
for development of COPD.
Recently, a large prospective cohort study (ECLIPSE)
was initiated to study the natural course of COPD in
order to gain more insight into the underlying pathogen-
etic mechanisms.38 The ECLIPSE study is a 3-year obser-
vational study including current and ex-smoking COPD
patients and healthy controls with and without a smoking
history. Indeed, the ECLIPSE study conﬁrmed that the
clinical manifestations of COPD are highly variable and
that the degree of airﬂow limitation does not capture the
heterogeneity of the disease.39 In particular, the rate of
change in FEV1 among patients with COPD was highly
variable, with increased rates of decline among current
smokers, patients with bronchodilator reversibility and
with emphysema.40 Several new susceptibility genes have
been identiﬁed in the ECLIPSE study,41 42 as well as
potentially useful biomarkers.43–45 However, in contrast
to our study, ECLIPSE does not include young subjects
and is, therefore, not able to investigate the susceptibility
for COPD at a young age. ECLIPSE investigates aspects of
systemic inﬂammation (C reactive protein, TNF-α, IL-6,
IL-8, serum surfactant protein D (SP-D)), but does not
investigate the activation state of circulating neutrophils
and lymphocytes, nor does it perform unbiased prote-
omic analyses of epithelial lining ﬂuid and peripheral
blood neutrophils. Therefore, our study will complement
ECLIPSE data by focusing on the pathogenesis of local
and systemic inﬂammation by using unique approaches
to link genomic and inﬂammatory phenotypes in all
stages of COPD from preclinical to advanced disease.
The present study has already been started and recruit-
ment is still ongoing. The study population has been
described in ClinicalTrial.gov (NCT00807469 and NCT
00850863) and was divided into nine groups. Initially, we
planned to distinguish susceptible individuals into a ‘sus-
ceptible’ and ‘very susceptible’ group. The group of ‘old’
very susceptible individuals should include early-onset
COPD (FEV1/FVC<70%, FEV1<40% predicted, age<53
years) and COPD with low number of pack years (FEV1/
FVC<70%, FEV1<80% predicted, pack years <5). The
group of ‘young’ very susceptible individuals should have
included young individuals with family members with
early-onset COPD or COPD with low smoke exposure.
Despite an intensive search among lung transplantation
(LTx) candidates/recipients and their family members
we were not able to recruit this group in sufﬁciently high
numbers. Therefore, we decided to combine the suscep-
tible and very susceptible groups.
COPD is often accompanied by different comorbidities,
especially cardiovascular conditions, which also affect the
prognosis of the disease as well as quality of life and cost of
COPD.46 47 Consequently, we do not exclude subjects with
cardiovascular comorbidity conditions unless the condi-
tion was acute or too severe. We use the selected grades
1–3 comorbidity list in ACE-279 to exclude patients with
comorbidities within grade 2 or 3 in all organ systems
except the respiratory system. We also exclude subjects
with systemic inﬂammatory diseases such as rheumatoid
arthritis, because we might investigate systemic inﬂamma-
tion related to other systemic inﬂammatory diseases.
In conclusion, this study will provide valuable informa-
tion regarding the pathogenetic mechanisms underlying
the development of COPD, which in the future will help
us to develop new targets for the management of differ-
ent phenotypes of COPD.
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